Ranbaxy and EPIRUS to sign licensing agreement

For biosimilar product

Ranbaxy Laboratories and EPIRUS Switzerland GmBH have announced the signing of licensing agreement for BOW015, a biosimilar version of Infliximab.

Powered by Capital Market - Live News